Insulet Co. (NASDAQ:PODD) Shares Sold by Advisors Capital Management LLC

Advisors Capital Management LLC decreased its stake in shares of Insulet Co. (NASDAQ:PODD) by 4.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,051 shares of the medical instruments supplier’s stock after selling 129 shares during the period. Advisors Capital Management LLC’s holdings in Insulet were worth $797,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the company. Horizon Investments LLC increased its holdings in shares of Insulet by 3.1% in the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock valued at $362,000 after acquiring an additional 42 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Insulet by 1.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after purchasing an additional 43 shares during the last quarter. Graypoint LLC increased its stake in Insulet by 5.3% during the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after purchasing an additional 47 shares during the last quarter. Wilmington Savings Fund Society FSB raised its holdings in shares of Insulet by 9.6% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 47 shares during the period. Finally, Envestnet Portfolio Solutions Inc. lifted its position in shares of Insulet by 2.3% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier’s stock worth $552,000 after buying an additional 48 shares during the last quarter.

Analyst Ratings Changes

Several research firms recently weighed in on PODD. TD Cowen increased their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Canaccord Genuity Group raised their price target on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Stifel Nicolaus upped their price objective on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. Royal Bank of Canada started coverage on Insulet in a research report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 target price on the stock. Finally, StockNews.com downgraded shares of Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.06.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $255.47 on Tuesday. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a fifty day moving average price of $266.08 and a two-hundred day moving average price of $260.72. The firm has a market cap of $17.94 billion, a P/E ratio of 44.12, a PEG ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Research analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insider Activity at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now directly owns 3,231 shares of the company’s stock, valued at $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.